Synonyms: PF-07304814 | PF07304814
Compound class:
Synthetic organic
Comment: PF-07304814 is a SARS-CoV-2 3CL protease (Mpro) inhibitor from Pfizer. The structure of PF-07304814 is identical to that of the INN lufotrelvir (from proposed list 125, July 2021). PF-07304814's phosphate group (which improves solubility) is cleaved in vitro to release the active antiviral PF-00835231 [1-2]. PF-00835231 was originally developed as a SARS-CoV Mpro inhibitor in response to the 2002-2003 outbreak [3]. Like remdesivir, PF-07304814 is administered by intravenous infusion.
|
|
References |
1. Baig MH, Sharma T, Ahmad I, Abohashrh M, Alam MM, Dong JJ. (2021)
Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study. Molecules, 26 (6): 1678. [PMID:33802860] |
2. de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A et al.. (2021)
A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19. J Virol, 95 (7). [PMID:33622961] |
3. Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, He M, Hogan RJ, Kozminski K, Li LY et al.. (2020)
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. J Med Chem, 63 (21): 12725-12747. [PMID:33054210] |